How we manage medication-related osteonecrosis of the jaw

Abstract

Bone-modifying agents (BMAs) are integral to managing patients with advanced cancer. They improve quality of survival by reducing skeletal-related events, treating hypercalcaemia and chemotherapy-induced bone loss (Coleman in Clin Cancer Res 12: 6243s–6249s, 2006), (Coleman in Ann Oncol 31: 1650–1663, 2020). Two decades ago, medication-related osteonecrosis of the jaw (MRONJ) was first reported following BMA therapy (Marx in J Oral Maxillofac Surg 61: 1115–1117, 2003). The risk of MRONJ extends over a decade following BMA treatment with bisphosphonates, complicating dental care such as extractions. In addition, MRONJ has been reported following additional therapies such as antiangiogenic agents, cytotoxic agents, immunotherapy, and targeted agents. The use of BMAs in the curative and adjuvant cancer setting is increasing, consequently the implication of MRONJ is growing. Over the past 20 years, the literature has consolidated major risk factors for MRONJ, the pathophysiology and management strategies for MRONJ. Our review aims to document the development of MRONJ preventative and management strategies in cancer patients receiving a BMA. The authors advocate the incorporation of dental oncology strategies into contemporary cancer care, to optimise long-term quality of survival after cancer treatment.

Introduction

Two decades ago, Marx described medication-related osteonecrosis of the jaw (MRONJ) as an emerging clinical entity in patients receiving bisphosphonate therapy [3, 4]. MRONJ is now an established condition defined by exposed bone that can be probed through an intra- or extra-oral fistula(e) in the maxillofacial region which has persisted for more than 8 weeks. The patient must have no history of radiation therapy or metastatic disease to the jaws and has had a current or previous treatment regime with antiresorptive therapy or antiangiogenic medications [4]. At present, bone-modifying agents (BMAs) are commonly prescribed to patients with prostate (85%), breast (70%), lung (40%), kidney (40%) cancer, and multiple myeloma (95%), to reduce the risk of skeletal-related events (SREs), chemotherapy-induced bone loss and to treat hypercalcaemia. Their effectiveness in reducing SREs has led to their integration into guideline based cancer care [1, 2, 5, 6]. Practising oncologists need to know how to identify at risk patients, and to integrate onco-dental strategies into multidisciplinary cancer care.

Over the past two decades, more than 1,500 articles have been published on MRONJ, reflecting its significant relevance. However, this increasing clinical relevance is compounded by the historical under-appreciation of dental diseases worldwide. In May 2021, the World Health Assembly (WHA) introduced the resolution WHA 74.5 as a global strategy to combat oral diseases. Dental disease remains the highest non-communicable disease over the life span of MRONJ [7, 8].

The purpose of this review is to provide practical guidance for oncologists prescribing BMAs, and to emphasise the need for further integration of dental oncology into cancer care.

Clinical features of MRONJ

MRONJ can present with a variety of  clinical manifestations: exposed bone in the oral cavity, diffuse jaw pain, swelling, purulence, mobile teeth, fistula (intra- or extra-oral), sinusitis, pathological fracture, sensory changes, and maxillofacial deformity. The mandible is more commonly affected than the maxilla [9], (Fig. 1, 2). Radiographic analyses can aid with accurate size definition  [10]. In advanced cases, the cyclical nature of superinfection and remission is prominent along with pain and debilitation [11]. Mucosal breakdown is not always necessary to define MRONJ, and non-exposed regions of bone with exclusion of other disease processes can encompass the earliest stage of MRONJ [4].

MRONJ is staged most commonly using The American Association of Oral and Maxillofacial Surgery (AAOMS) staging systems, as shown in Table 1 [4]. McMahon et al. [12], Bedogni et al. [13] and Yoneda et al. [14] all require radiographic findings to calibrate staging.

Table 1 America Association of Oral and Maxillofacial (AAOMS) staging system for MRONJ [1]

Fig. 1

Is a clinical photograph of stage 2 (AAOMS) MRONJ—infected exposed mandible

Fig. 2

Is a clinical photo which highlights saliva extruding through the orocutaneous fistula in the right mandible (AAOMS Stage 3)

Fig. 3

Highlights local factors implicated in the pathophysiology of MRONJ [4, 46]

Fig. 4

Depicts the management protocol for MRONJ and preventative strategies for patients intended for BMA prescription [4, 46]

Fig. 5

Depicts the factors affecting the patient’s journey and dental experience following the use of BMAs

Extension of MRONJ into the mandible or maxilla can result in large, exposed necrotic regions of bone with associated sensory deficit, pathological fracture, or an oroantral fistula in advanced stages (Fig. 2). MRONJ can affect a patient’s quality of life (QoL), including their functional capacity and psychological well-being [15]. The impact of MRONJ on QoL is poorly documented in the literature. Consequently, psychological impact, functional limitation, physical disability, and deformity are incorporated into the Oral Health Impact Profile-14 (OHIP-14) for the assessment of MRONJ on QoL. Psychological discomfort was rated as the greatest negative impact factor on the OHIP-14 questionnaire for MRONJ [15].

Epidemiology

The prevalence of MRONJ in patients with cancer ranges from 0 to 12% [16] while the incidence rates in patients with metastatic bone disease on zoledronic acid therapy also vary from 1.5 to 6% [4]. Receptor activator of nuclear factor kappa-beta ligand (RANK-L) inhibitors have been used as alternatives to bisphosphonates, with a reported incidence of MRONJ following subcutaneous denosumab ranging between 0.7 and 6.7% [17,18,19]. Incorporation of BMAs into adjuvant therapy poses a long-term MRONJ risk for patients treated with a curative intent. MRONJ was prevalent between 0.00 and 1.8% in clinical trials when antiresorptives were used in the adjuvant setting. The long-term risk of MRONJ is also relevant to this cohort and provides a cautionary message for clinicians regarding dental risk in this group [20,21,22,23,24,25,26].

A meta-analysis by Srivastava et al. concluded that a higher incidence of MRONJ is associated with dual therapy rather than a single antiresorptive or antiangiogenic therapy. Examples of dual therapy include the combination of two BMAs, concurrent use of BMAs with steroid administration or cyclin-dependent kinase 4/6 inhibitors (CDK 4/6,) [4, 27]. The use of polypharmacy and variable regimes of antiresorptives, antiangiogenics, folate antagonist, targeted agents and immunotherapies for cancer, implies a globalised difficulty to refine the exact risk of MRONJ [28,29,30,31,32,33,34,35].

Pathophysiology

The pathophysiology of MRONJ remains unproven however significant advances have been made over the past two decades to refine vital pathological processes [36], (Fig. 3). Alveolar bone is a highly active bone that is capable of rapid remodelling. The predilection of the jaw reflects the proximity of the bone to the oral mucosa and the oral microbiome. Dental infection and inflammatory processes have been implicated in MRONJ [37]. Pre-existing dental infection plays a significant role, which predisposes patients to MRONJ, which remains independent to a tooth extraction [38].

Site-specific jaw involvement has been attributed to bone remodelling inhibition, suppressed bone turnover, inflammation, infection, direct cellular toxic effects, angiogenesis inhibition, innate or acquired immune dysfunction, and genetic predisposition. The typical histological picture of osteonecrosis includes marrow fibrosis, hypovascularisation, and bacterial colonisation with inflammation [36, 39, 40]. Severe dental disease and infection coupled with osteoclast inhibition are predominant initiators of MRONJ [37, 41,42,43,44,45]. It is likely that its pathogenesis is multifactorial in a susceptible host exposed to BMA therapy.

Systemic risk factors contribute to the development of MRONJ in a susceptible patient. This immune compromise is compounded by acquired immune dysfunction seen in patients with medical comorbidities such as diabetes mellitus, rheumatoid arthritis, or immunocompromised states such as corticosteroid use and cytotoxic chemotherapy [47,48,49].

Treatment of MRONJ

There is no definitive cure for MRONJ; however, the ultimate goal is mucosal closure to optimise quality of life.

The management of MRONJ begins with a thorough medical, social, and dental history. Specific BMA regimens and exacerbating factors must be confirmed. Initial conservative treatment strategies play a vital role in the management of all stages of MRONJ and are a valuable adjunct to both medical and surgical treatments [50, 51]. Ruggiero et al. 2014 devised a treatment strategy based on staging and symptoms [16]. Antiseptic mouth wash, oral hygiene, patient education, and regular dental review (3-monthly) are basic conservative regimes for all stages of MRONJ [4, 41]. Stage 0 or 1 requires symptomatic control of pain and meticulous oral hygiene measures. Debridement of sharp spicules of necrotic bone may be also warranted [4], (Fig. 4).

Medical intervention

The medical management of MRONJ remains a viable option for patients. Data from a double-blinded, randomised control trial on the efficacy of teriparatide for the treatment of MRONJ reported higher MRONJ resolution rates in the treatment arm compared the placebo at 52 weeks [52]. Sim et al. noted a 45.4% resolution of MRONJ (radiographic and clinical improvement) compared to 33% resolution in the placebo group over 12 months using teriparatide [52], demonstrating the short-term use of teriparatide could be both an efficacious and safe medical strategies for the management of MRONJ [52]. The side effects profile of teriparatide includes nausea, anorexia, renal dysfunction and musculoskeletal pain which can be limiting factors [52]. The incidence of osteosarcoma increased in rats following the administration of teriparatide, however this dose-dependency was observed in toxicology studies in rats only [53]. Low dosing regimens prior to and following surgical interventions can offer superior outcomes to surgical intervention alone [54, 55]. A pathobiological explanation for the effects of teriparatide on MRONJ is derived from its osteoanabolic properties stimulating osteoblasts, reducing exposed bone volume and increasing mucosal coverage [52, 56]. Pentoxifylline and tocopherol (PENTE) has been originally cited for their benefits in the management of osteoradionecrosis [57]. Data were limited to 3 observational studies and 2 abstracts for the use of pentoxifylline and tocopherol in the medical management of MRONJ, however promising results were yielded from all studies [58]. These studies showed that PENTE reduced painful symptoms and promoted new bone formation in a well-tolerated regime of PENTE for the management of MRONJ [39]. Patel et al. concluded the prophylactic use of PENTE prior to a dental extraction was superior to placebo when used in patients at risk of osteoradionecrosis [40]. The role of antibiotics relates directly to prominent micro-organisms that reside in the biofilm in the oral cavity, Actinomyces species [29, 50]. Beta lactams remain the antibiotic of choice [59]. Hospitalisation and intravenous antibiotics may be required in indicated clinical and systemic condition.

Bio-stimulation modalities such as hyperbaric oxygen, low-intensity laser, and medical ozone therapy, offer no definitive evidence to support cure or cessation of progression of MORNJ [40, 47, 49, 60,61,62,63]. Recombinant human bone morphogenic protein-2 is a transforming growth factor beta and approved as a bone graft substitute. Its use has been suggested in the treatment of MRONJ, however further research is implicated to define its efficacy in this cohort [64, 65]. Photobiomodulation (PBM) therapy has evoked interest in the treatment of acute oral mucositis following radiation therapy in head and neck oncology patients. The WALT position paper 2022 also reviewed its application in the treatment of MRONJ [66]. PBM has been incorporated into MRONJ treatment regimens, proving beneficial as an adjunct to surgical and antibiotic therapy [67]. The use of low-level laser therapy was proposed following the WALT report for the management of MRONJ [66]. Inflammatory suppression signalling and low-level laser therapy have shown promising results in in vitro studies for gingival wound healing and subsequent bone regeneration following tooth extraction in zoledronate treated specimens [68]. Sole medical management strategies for MRONJ have been based on case reports and small clinical trials, to optimise the potential synergistic effects of multiple medical management strategies for MRONJ particularly in the maxilla where complex surgical intervention was contraindicated in oncology patients [69]. A multimodality care algorithm was proposed including chlorhexidine with exposed bone, antibiotics when clinically required, PBM delivered by medical and patient at home LED-based PBM device, teriparatide (20 µg per day for 2 months), and pentoxifylline and tocopherol [69].

Surgical intervention

Surgical management was initially used to palliate MRONJ, which was unresponsive to conservative and medical management [46]. Surgical management is introduced earlier in the treatment cycle in less aggressive surgical interventions such as superficial debridement, sequestrectomy, and alveoloplasty to achieve necrotic bone removal and primary mucosal closure. Tensionless mucosal flaps are imperative to optimise healing, help stimulate angiogenesis and basal lamina signalling pathways [4, 9, 70,71,72,73]. CT-based surgical planning plays a vital role prior to surgical management which helps to accurately define the affected, bone defect [74]. Marcianò et al., reported on a 10-year retrospective, single-centre study on surgical outcomes for MRONJ [75]. A surgical decision tree was devised based on their findings of 128 MRONJ surgeries, in both curative and palliative cases, to guide the hard and soft tissue management of MRONJ. They advocated the use of piezoelectric devices in saucerisation and additional osteoplasty measures in more aggressive alveolar-block resections to eliminate residual bone asperity [75]. Radical decortication, submarginal bone resection, rim mandibulectomy, and local resection are used for progressively advanced stage surgical procedures for MRONJ [76]. Replacement of tissue with biocompatible scaffolds and osteogenic potentiator cells such as buccal fat pad, and restoration of form and function using free tissue transfer flaps may be utilised following resection [61]. Free tissue transfer flaps have been used to address large defects in stage 3 patients and case studies have reported promising success rates of 96% [76]. Fibula free flaps have been favoured in these oncology patients due to low incidence of primary bone malignancy or metastatic bone disease [77]. Soft tissue management in deficient cases may require advancement of mucoperiosteal flaps, mylohyoid flaps or pedicled buccal fat pad flaps to ensure primary closure and provide additional protection against wound dehiscence. The use of locally derived growth factors such as Platelet Rich in Growth Factors (PRGF) and Platelet-Rich Plasma (PRP) remains controversial [9]. Surgical intervention can be associated with a deterioration in a patient’s clinical status which must also be appreciated by clinicians [78]. Case selection and identification of exacerbation factors are important pre-surgical considerations [79].

The literature offers a heterogenous range of treatment regimes, which often lack standardisation, leading to uncertainty about effective treatment modalities. Migliorati et al. reported on an array of treatment modalities in oncology patients on a BMA. Medical therapy resulted in resolution of MRONJ in 17.6% (n = 120), surgical debridement in 17.3% (n = 118) and surgical flap and / or resection in 46.3% (n = 316). Mucosal healing was reported in 56.2% (n = 380) [80]. Host, medical, dental and treatment variabilities contribute to the heterogenous response to therapies and management challenges [80, 81] (Fig. 5).

Prevention of MRONJ

Primary prevention of MRONJ—before and during treatment with a bone-modifying agent

Preventative dental therapy prior to BMA has been shown to reduce the incidence of MRONJ compared to oncology populations without a pre-therapeutic preventative dental programme [51, 82,83,84]. Most recent documents to guide MRONJ preventative regimes include the Cochrane Oral Health, 2022 (3rd version) [85], American Association of Oral and Maxillofacial Surgeons, 2022 (4th version) [4] and Italian Society of Maxillofacial Surgery / Italian Society of Oral Pathology and Medicine, 2023 (3rd version) [86] which define timelines for dental review regimes (3-monthly) for patients on a BMA [85], MRONJ risk factor identification [4], the use of antibiotic therapy and primary closure following an extraction [86, 87]. The placement of implants in high-risk oncology patients following BMA therapy was contra-indicated [4, 86]. Another cornerstone document which provides guidance for the prevention and management of MRONJ is the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology/American Society of Clinical Oncology (MASCC/ISOO/ASCO) Clinical Practical Guidance, 2019 (1st version) [88]. This document was produced by an expert panel of oncologist based on 10 randomised control trials. It reinforces the necessity of multidisciplinary co-ordination of care between specialities, does not advocate the use of drug holidays, guides MRONJ risk stratification and could not conclude on the role of prophylactic antibiotic therapy with dental extractions [88, 89].

Primary prevention predominantly aims to reduce or eliminate dental risk factors [90]. Bramati et al. demonstrated a decreased incidence of MRONJ following a dental preventative programme, from 11 to 7% [91]. Timely dental care screenings facilitate the removal of non-restorable teeth or those with periapical infection, address periodontal disease, commencement of a stringent hygiene protocol to maintain a high standard of oral health, occlusal adjustment, parafunctional protection, atraumatic-fitting dental prostheses, topical remineralising therapy and caries control [46, 51, 82, 83]. MRONJ risk reduction, smoking cessation, dental hygiene education, and promotion of 3-monthly dental reviews must be addressed in the primary preventative stage [85]. It is important to note that for a new adult oncology patient, co-ordination of dentistry predominantly depends on patient-driven attendance and self-reliance [92]. The importance of routine dental assessments at the beginning of systemic anti-cancer therapy involving BMAs should be integrated into routine cancer care [93]. The role of the dental auxiliaries, such as dental hygienists, in regular professional supragingival and subgingival scaling has proven to be a beneficial preventative strategy [51]. Early detection of dental diseases throughout the course of BMA treatment can reduce the requirement for invasive dental procedures [90]. A randomised control trial on the impact of preventative dental treatment strategies and 3-monthly dental reviews following BMA administration were associated with a 2.59 reduced risk reduction for MRONJ [94].

Secondary prevention of MRONJ

Secondary prevention aims to facilitate the early detection of MRONJ. Regular routine dental care permits the detection of MRONJ in earlier stages of development, which tend to have more predictable outcomes and reduced morbidity [90]. Coordination of regimented dental surveillance before, during and after patient exposure to a BMA minimises the risk of MRONJ [83, 85]. Delaying the BMA may be implemented if systemic factors permit to achieve dental fitness [95].

Drug holidays have yet to be proven as definitively effective strategies to prevent MRONJ; their benefits are unclear, and the literature remains divided [4, 90]. The term drug holiday can pose misconceptions related to a temporary suspension of BMA prior to a dental intervention or the cessation of BMA due to an MRONJ diagnosis [90]. The former is only accepted as a temporary suspension, and the length of a drug holiday is specific to each medication depending on mode of action and half-life [97]. The foundation of a drug holiday is despite the 11.2 year half-life of oral bisphosphonates, bone marrow stem cells and osteoclast precursors have the ability to regenerate to sufficient numbers to remodel and renew bone during the healing process. However, an effective drug holiday is not achievable in cancer patients for intravenous bisphosphonates or subcutaneous denosumab (120 mg/3 monthly) for skeletal-related events because of the more rapid and gradual bone depletion of bone marrow osteoclast precursor cells and potency of the therapy in the oncology setting [46]. Drug holidays for osteoporotic patients should be utilised under the prescribing physician’s responsibility; however, this preventative strategy may be ineffective for the oncology patient. A recent randomised clinical feasibility trial conducted with antiresorptive therapies demonstrated no prevention of MRONJ development within a 4-month drug holiday after surgical tooth removal in the oncology cohort. The authors noted a decline in patient-reported health outcomes during the drug holidays compared with drug continuation [98]. There are no randomised control trials in this field, and despite low-quality evidence, the benefit of a drug holiday for the prevention of MRONJ is not warranted [98,99,100]. There are no bone turnover biomarkers which are currently effective for detection or monitoring of MRONJ. C-terminal crosslinking telopeptide, vascular endothelial growth factor activity, endocrine function, and parathyroid hormone levels have yet to be proven as reliable indicators in this field [4].

Current BMA prescription trends in breast and prostate cancer with bone metastases, have advocated the de-escalation of antiresorptive therapy usually two years after cancer treatment. This step towards reducing the administration of antiresorptive drugs has been shown to be safe, and does not change the risk or incidence of SREs, health-related quality of life (HRQL)-physical subdomain, pain and symptomatic skeletal-related events (SSE)-free survival [101, 102]. Data appears to be more confounding for bisphosphonates compared to RANK-ligand inhibitors [101, 103].

Team-work

It is important to address healthcare inadequacies such as the burden of dental disease in vulnerable cohorts, to create reciprocal interactions and improve healthcare services [104]. Overcoming challenges in healthcare is a universal dilemma that is overlooked across a vast array of disciplines [105,106,107].

Future directions

In the absence of proactive dental oncology protocols, we anticipate that MRONJ will become increasingly relevant in the coming decades. To date, 1500 research articles have been published in the literature on MRONJ with no definitive consensus about the management of MORNJ, which heightens the importance of the role of preventative care and regular dental review for these patients. The level of evidence for management strategies is predominantly derived from cohort and case–control studies as well as systematic reviews of them. The restriction of lower-quality evidence in the sphere of MRONJ still defines the progression of information regarding its aetiology, epidemiology and management [85]. The authors appreciate the challenges of randomised control trials of MRONJ and valid ethical concerns.

An additional exacerbating factor in recent high-risk cohorts is the use of drugs that increase the existing toxicity of BMAs. For example, CDK 4/6 inhibitors commonly used to treat hormone sensitive breast cancers, can increase MRONJ risk when prescribed in conjunction with BMAs [27].

The oncology cohort remains the most vulnerable group for potential MRONJ development, both systemically and pharmacologically. The disease entity relies on preventative protocols before BMA therapy to reduce the rate of MRONJ development. Treatment protocols have remained relatively similar over the past 20 years as conservative first-line treatments to help control smaller regions of exposed bone. Surgical intervention plays a role in the management of MRONJ; however, this can be unpredictable and can be attributed to the multifactorial nature of the host and disease entity [4, 71, 73, 108]. Medical management can offer benefit to patients with MRONJ, in particular the use of teriparatide in the management of MRONJ [52, 56].

For practising oncologists today, MRONJ is a risk for patients in both palliative and curative settings. This review highlights the importance of dental preventive strategies and the array of current management strategies under investigation.

Recommendations

Take home guidance for the treating oncologist

Before treatment with a bone-modifying agent

• Patient information—risk of MRONJ [4]

• Liaison with dental team prior to BMA administration [51]

• Facilitate dental assessment [92, 93]

• Achieve dental fitness prior to BMA [82]

• Ensure dental review regime in place [90]

During treatment with a bone-modifying agent

• Liaison with dental team to ensure maintenance regime [51]

• Encourage denture hygiene, topical fluoride therapy, professional cleanings and interdental cleaning aids [51]

• Multidisciplinary care prior to dental intervention [90]

• Immediate dental review if oral adverse effect suspected [4]

After treatment with a bone-modifying agent

• Liaison with dental team to ensure maintenance regime (3-monthly) [90]

• Multidisciplinary care prior to dental intervention [4]

• Patient information and impact of BMA half-life on dental care [85]

Suspected MRONJ

• Recommendation of chlorhexidine mouthwash [16]

• Prompt referral to an oral surgeon or maxillofacial unit [51]

• Correspondence including antiresorptive/angiogenic history [9]

Commonly asked questions in the oncology cohort

Who should I refer to if a dental extraction is needed?

Prior to a BMA, the patient’s general dental practitioner is suitable to extract a tooth.

After receiving a BMA, a dentist, oral surgeon (or maxillofacial surgeon) is the most appropriate [109].

Do all patients need antibiotics?

For patients with a previous or current history of BMAs and a requirement for a tooth extraction; pre- and post-operative antibiotics should be considered by the dental surgeon. Penicillin-based antibiotics (amoxicillin ± clavulanic acid) or clindamycin in patients with penicillin allergies are recommended [4, 85, 90, 96].

Do drug holidays work?

Uncertainty remains regarding the efficacy of a drug holiday; however, the literature favours its ineffective nature in the prevention of MRONJ in the oncology cohorts. The authors do not advocate a drug holiday in this specific cohort [4, 46, 90, 98,99,100]. Delaying BMA therapy if systemically permitted, may allow patients to reach dental fitness and reduce the risk of MRONJ [4].

Is it ever safe to reintroduce BMAs in patients with a history of MRONJ?

Case-based assessment is necessary in conjunction with communication with the treating dental surgeon to determine the status of MRONJ and the systemic requirements of the BMA. There are no data available to answer this clinical question. If avoidable, the reintroduction of the BMA would be ill-advised. The development of a real-world data base of such a cohort would be helpful.